Atnaujinkite slapukų nuostatas

Palliative Care Formulary 8th edition [Minkštas viršelis]

Edited by , Editor-in-chief , Editor-in-chief
  • Formatas: Paperback / softback, 992 pages, aukštis x plotis x storis: 216x138x42 mm
  • Išleidimo metai: 04-Aug-2022
  • Leidėjas: Pharmaceutical Press
  • ISBN-10: 0857114379
  • ISBN-13: 9780857114372
Kitos knygos pagal šią temą:
  • Formatas: Paperback / softback, 992 pages, aukštis x plotis x storis: 216x138x42 mm
  • Išleidimo metai: 04-Aug-2022
  • Leidėjas: Pharmaceutical Press
  • ISBN-10: 0857114379
  • ISBN-13: 9780857114372
Kitos knygos pagal šią temą:

The eighth edition of the Palliative Care Formulary (PCF), from Pharmaceutical Press, the Royal Pharmaceutical Society’s knowledge business, is an essential resource for health professionals who care for patients with progressive end-stage disease.

Although written primarily with cancer patients in mind, PCF8 contains specific material relating to several other life-limiting diseases e.g. COPD, end-stage heart failure, renal and hepatic failure, and end-stage Parkinson's disease.

PCF8 also includes several Quick Clinical Guides covering key topics in palliative care and designed for everyday use.

Grounded in clinical practice, this comprehensive title includes independent information about drugs used in palliative care, highlighting off-label indications or routes, and dealing with the administration of multiple drugs by continuous subcutaneous infusion.
PCF8 consists of 35 chapters and appendices; of the monographs, there is one renamed (Tricyclic antidepressants) and two discontinued (Carbamazepine and Danazol). 

Key monographs in PCF8 have been fully reviewed and revised for this edition, including all analgesics, antidepressants, bisphosphonates, denosumab, drugs and fitness to drive, renal impairment and swallowing difficulties and enteral feeding tubes.



The eighth edition of the Palliative Care Formulary (PCF8), from Pharmaceutical Press, the Royal Pharmaceutical Society’s knowledge business, is an essential resource for health professionals who care for patients with progressive end-stage disease.

Although written primarily with cancer patients in mind, PCF8 contains specific material relating to several other life-limiting diseases e.g. COPD, end-stage heart failure, renal and hepatic failure, and end-stage Parkinson's disease.

Grounded in clinical practice, this comprehensive title includes independent information about drugs used in palliative care, highlighting off-label indications or routes, and dealing with the administration of multiple drugs by continuous subcutaneous infusion.

Updates in the new edition:

• Renamed monograph (Tricyclic antidepressants) and two discontinued - (Carbamazepine and Danazol).

Fully reviewed and updated monographs with the latest references and evidence for all uses in palliative care including for:

• All the individual strong opioid analgesic drug monographs and Quick Clinical Guides

• Antidepressants class and individual drug monographs

• Anti-epileptics class and individual drug monographs including a significantly updated section on the management of seizures and the use of subcutaneous levetiracetam

• Bisphosphonates monograph including the 2020 ESMO clinical practice guidelines and a new joint summary table for the indications of use for bisphosphonates and denosumab in palliative care

• Denosumab monograph including the 2020 ESMO clinical practice guidelines

• Drugs and fitness to drive chapter including updates to the summary table of the available evidence for sedative drugs

• Renal impairment chapter including significant changes to the sections on assessing renal function, and opioid use in renal impairment

• Drug administration to patients with swallowing difficulties or enteral feeding tubes chapter including a new step-wise approach for alternative formulations, and a fully updated table on commonly used alternative products

Targeted updates to monographs including:

• H2-receptor antagonists monograph updated to reflect the alternative oral and parenteral options due to the world-wide absence of ranitidine

• Proton pump inhibitors monograph significant updates to the parenteral administration section

• Clonidine monograph, involving significant updates to the dose and use section and a new summary of dexmedetomidine use

• Drugs for diabetes monograph updated to include the 2021 Diabetes UK guidelines and the 2021 Joint British Diabetes Societies Inpatient Care Group guidelines. Significant changes to the sections on corticosteroid-induced diabetes mellitus, the management of hypoglycaemia, and the management of spikes of hyperglycaemia in the last few weeks of life

• Systemic corticosteroids significant updates on the risks of adrenal insufficiency including information about the new steroid emergency card and information on the evidence of use for appetite stimulation

• Anaphylaxis appendix updated to reflect the 2021 Resuscitation Council UK guidelines.

PCF8 also includes several Quick Clinical Guides covering key topics in palliative care and designed for everyday use.

Preface to the eighth edition xi
How PCF is constructed xii
Getting the most out of PCF xiv
The use of medicinal products beyond (off-label) and without (unauthorized) marketing authorization xix
Drug names xxv
Abbreviations xxvii
Part 1 Drug monographs
1 Gastro-intestinal system
1(66)
Antacids and antiflatulents
1(3)
Antimuscarinics
4(18)
Prokinetics
22(5)
H2-receptor antagonists
27(4)
Proton pump inhibitors
31(5)
Loperamide
36(4)
Laxatives
40(21)
Topical products for haemorrhoids
61(2)
Pancreatin
63(4)
2 Cardiovascular system
67(96)
Furosemide
67(6)
Spironolactone
73(4)
Systemic local anaesthetics
77(5)
*Clonidine
82(6)
Glyceryl trinitrate
88(4)
Nifedipine
92(3)
Anticoagulants
95(19)
Haemostatics
114(7)
3 Respiratory system
121(1)
Bronchodilators
121(19)
Inhaled corticosteroids
140(4)
Oxygen
144(10)
Drugs for cough
154(9)
4 Central nervous system
163(158)
Benzodiazepines and Z-drugs
163(17)
Melatonin
180(4)
Antipsychotics
184(26)
Antidepressants
210(36)
*Psychostimulants
246(5)
*Cannabinoids
251(7)
Anti-emetics
258(22)
Anti-epileptics
280(41)
5 Analgesics
321(186)
Principles of use of analgesics
321(4)
Adjuvant analgesics
325(6)
Paracetamol
331(8)
Nefopam
339(2)
Non-steroidal anti-inflammatory drugs (NSAIDs)
341(35)
Weak opioids
376(13)
Strong opioids
389(101)
Opioid antagonists (therapeutic target within the CNS)
490(10)
Opioid antagonists (therapeutic target outside the CNS)
500(7)
6 Infections
507(28)
Antibacterials in palliative care
507(4)
Oral candidosis
511(4)
Metronidazole
515(3)
Rifampicin
518(3)
Urinary tract infections
521(8)
Cellulitis in a iymphoedematous limb
529(6)
7 Endocrine system and immunomodulation
535(74)
Bisphosphonates
535(14)
Denosumab
549(7)
Systemic corticosteroids
556(12)
Demeclocycline
568(4)
Desmopressin
572(5)
Drugs for diabetes mellitus
577(14)
*Octreotide
591(8)
Progestogens
599(4)
*Thalidomide
603(6)
8 Urinary tract disorders
609(14)
Tamsulosin
609(2)
Urinary antimuscarinics
611(5)
Methenamine hippurate
616(2)
Catheter patency solutions
618(2)
Discoloured urine
620(3)
9 Nutrition and blood
623(26)
Anaemia
623(7)
Ascorbic acid (vitamin C)
630(2)
Vitamin K
632(3)
Potassium
635(3)
Magnesium
638(6)
Zinc
644(5)
10 Musculoskeletal and joint diseases
649(16)
Depot corticosteroid injections
649(2)
Rubefacients and other topical products
651(4)
Skeletal muscle relaxants
655(10)
11 Ear, nose and oropharynx
665(12)
Mouthwashes
665(1)
Artificial saliva
666(2)
Pilocarpine
668(1)
Drugs for oral inflammation and ulceration
669(5)
Cerumenolytics
674(3)
12 Skin
677(14)
Emollients
677(8)
Topical antipruritics
685(3)
Barrier products
688(3)
13 Anaesthesia
691(16)
*Ketamine
691(11)
*Propofol
702(5)
Part 2 Prescribing in palliative care
14 Prescribing in palliative care
707(14)
15 Anticipatory prescribing in the community
721(4)
16 Prescribing for children
725(6)
17 Renal impairment
731(22)
18 Hepatic impairment
753(28)
19 Variability in response to drugs
781(16)
20 Prolongation of the QT interval in palliative care
797(8)
21 Drug-induced movement disorders
805(4)
22 Drugs and fitness to drive
809(6)
23 Taking controlled and prescription drugs to other countries
815(2)
24 Obtaining specials
817(4)
25 Management of postoperative pain in opioid-dependent patients
821(4)
26 Drugs for pruritus
825(10)
27 Oral nutritional supplements
835(18)
Part 3 Routes of administration
28 Drug administration to patients with swallowing difficulties or enteral feeding tubes
853(34)
29 Continuous subcutaneous drug infusions
887(14)
30 Transdermal patches
901(3)
31 Nebulized drugs
904(4)
32 Spinal analgesia
908(12)
Appendices
A1 Anaphylaxis
920(5)
A2 Opioid dose conversion ratios
925(8)
A3 Compatibility charts
933(18)
Indexes
Drugs 951(6)
Topics 957